Fierce Biotech

FDA puts clinical hold on Regenxbio gene therapies weeks before approval ruling

A central nervous system (CNS) tumor has prompted the FDA to place clinical holds on two Regenxbio gene therapies, including ...
Nasdaq

REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022

RGX-111, a potential one-time gene therapy for MPS I, is well-tolerated across two dose levels, with no drug-related serious adverse events Biomarker and neurodevelopmental assessments indicate ...
WPRI 12

Additional Positive Interim Data from Phase I/II Trial of REGENXBIO'S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium™

ROCKVILLE, Md., Feb. 24, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive interim data from the Phase I/II trial of RGX-111 for the treatment of severe Mucopolysaccharidosis ...
Nasdaq

REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I

ROCKVILLE, Md., Dec. 8, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it has completed dosing in the expanded Cohort 2 of the Phase I/II trial of RGX-111 for the treatment of ...